Audrey Grain

Dr. Audrey Grain


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RCRaphael Carapito
Raphael Carapito
MKMartina Konantz
Martina Konantz
CPCatherine Paillard
Catherine Paillard
Zhichao MiaoZhichao Miao
Zhichao Miao
APAngélique Pichot
Angélique Pichot
SBSeiamak Bahram
Seiamak Bahram
Shwachman-Diamond syndrome (SDS) (OMIM #260400) is a rare inherited bone marrow failure syndrome (IBMFS) that is primarily characterized by neutropenia and exocrine pancreatic insufficiency. Seventy-five to ninety percent of patients have compound heterozygous loss-of-function mutations in the Shwachman-Bodian-Diamond syndrome (sbds) gene. Using trio whole-exome sequencing (WES) in an sbds-negative SDS family and candidate gene sequencing in additional SBDS-negative SDS cases or molecularly undiagnosed IBMFS cases, we identified 3 independent patients, each of whom carried a de novo missense variant in srp54 (encoding signal recognition particle 54 kDa). These 3 patients shared congenital neutropenia linked with various other SDS phenotypes. 3D protein modeling revealed that the 3 variants affect highly conserved amino acids within the GTPase domain of the protein that are critical for GTP and receptor binding. Indeed, we observed that the GTPase activity of the mutated proteins was impaired. The level of SRP54 mRNA in the bone marrow was 3.6-fold lower in patients with SRP54-mutations than in healthy controls. Profound reductions in neutrophil counts and chemotaxis as well as a diminished exocrine pancreas size in a SRP54-knockdown zebrafish model faithfully recapitulated the human phenotype. In conclusion, autosomal dominant mutations in SRP54, a key member of the cotranslation protein-targeting pathway, lead to syndromic neutropenia with a Shwachman-Diamond–like phenotype.

14 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
BCBéatrice Clémenceau
Béatrice Clémenceau
TGThierry A. Guillaume
Thierry A. Guillaume
MCMARIANNE COSTE-BUREL
MARIANNE COSTE-BUREL
PPPIERRE PETERLIN
PIERRE PETERLIN
AGAlice Garnier
Alice Garnier
PCPatrice Chevallier
Patrice Chevallier
Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2 vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell transplantation (Allo-HSCT), especially within the first post-transplant years where immunosuppression is more profound and harmful. Methods: SARS-CoV-2 Spike protein-specific T-cell responses were explored after two doses of BNT162b2 mRNA vaccine in 45 Allo-HSCT recipients with a median time from transplant of less than 2 years by using INF-γ ELISPOT assay and flow-cytometry enumeration of CD4+ and CD8+ T lymphocytes with intracellular cytokine production of IFN-γ and TNF-α. Results: A strong TNF-α+ response from SARS-CoV-2-specific CD4+ T-cells was detected in a majority of humoral responders (89%) as well as in a consistent population of non-humoral responders (40%). Conclusions: T-cells are likely to participate in protection against COVID-19 viral infection, even in the absence of detectable antibody response, especially in the first years post-transplant in Allo-HSCT recipients.

6 March 2025 in Blood
Verified
Journal Article
Closed access
JTJulian Thalhammer
Julian Thalhammer
EJEric Jeziorski
Eric Jeziorski
PMPerrine Marec-Bérard
Perrine Marec-Bérard
MBMohamed Aziz Barkaoui
Mohamed Aziz Barkaoui
APAnne Pagnier
Anne Pagnier
JDJean Donadieu
Jean Donadieu
Hematological involvement (HI) is one of the life-threatening risk organs (ROs) in Langerhans cell histiocytosis (LCH). Lahey criteria have defined HI since 1975 as hemoglobin <10 g/dL, platelets <100 × 109/L, leukopenia (white blood cell count <4 × 109/L), and/or neutrophils <1.5 × 109/L. Among the 2313 patients aged 7 g/dL and >20 × 109/L, respectively) and severe HI (SHI; ≤7 g/dL and/or ≤20 × 109/L). Each entity has different organ involvements, laboratory parameters, mutational status, blood BRAFV600E loads, drug sensitivities, and outcomes (MHI and SHI 10-year survival rates, 98% and 73%, respectively). Since 1998, mortality first declined with combination cladribine-cytarabine therapy and then with MAPK inhibitors since 2014. Forty-one patients (12%) developed neurodegenerative complications that have emerged as a risk for long-term survivors. These results suggest limiting the HI-RO definition to SHI, because it encompasses almost all medical complications of LCH. Future clinical trials might demonstrate that targeted therapy approaches would be better adapted for these patients, whereas MHI can be managed with classic therapies.

12 July 2023 in Acta Paediatrica
Verified
Journal Article
Closed access
AGAudrey Grain
Audrey Grain
MCMargaux Camuset
Margaux Camuset
CGChristèle Gras‐Leguen
Christèle Gras‐Leguen
JHJean‐Benoit Hardouin
Jean‐Benoit Hardouin
PSPauline Scherdel
Pauline Scherdel
DCDominique Caldari
Dominique Caldari

27 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
BCBéatrice Clémenceau
Béatrice Clémenceau
ABAmandine Le Bourgeois
Amandine Le Bourgeois
TGThierry A. Guillaume
Thierry A. Guillaume
MCMARIANNE COSTE-BUREL
MARIANNE COSTE-BUREL
PPPIERRE PETERLIN
PIERRE PETERLIN
PCPatrice Chevallier
Patrice Chevallier
A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 n = 40) or two (V4 n = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, p = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients.

4 May 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
AGAudrey Grain
Audrey Grain
FRFanny Rialland-Battisti
Fanny Rialland-Battisti
PCPatrice Chevallier
Patrice Chevallier
NBNicolas Blin
Nicolas Blin
JDJean-Hugues Dalle
Jean-Hugues Dalle
ABAndré Baruchel
André Baruchel